Table: Taisho Pharmaceutical HD -2018/19 group results
May 13 (Reuters)-
Taisho Pharmaceutical Holdings Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to NEXT
Mar 31, 2019 Mar 31, 2018 Mar 31, 2020 YEAR
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULTS FORECAST H1 FORECAST
Sales 261.55 280.09 253.50 126.50
(-6.6 pct) (+0.1 pct) (-3.1 pct) (-2.3 pct)
Operating 31.21 36.98 35.50 16.50
(-15.6 pct) (+15.7 pct) (+13.7 pct) (-2.9 pct)
Recurring 40.85 42.14 42.50 20.00
(-3.1 pct) (+10.8 pct) (+4.0 pct) (-11.9 pct)
Net
Net 48.59 31.68 28.50 13.50
(+53.4 pct) (+10.1 pct) (-41.4 pct) (-68.2 pct)
EPS 608.80 yen 396.54 yen 357.11 yen 169.15 yen
EPS Diluted 608.22 yen 396.20 yen
Ann Div 120.00 yen 110.00 yen 110.00 yen
-Q2 Div 50.00 yen 50.00 yen 50.00 yen
-Q4 Div 70.00 yen 60.00 yen 60.00 yen
NOTE - Taisho Pharmaceutical Holdings Co Ltd.
*Second Net profit row denotes profit attributable to owners ofthe parent
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4581.T
Recent news on Taisho Pharmaceutical Holdings Co
See all newsBrief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Squeeze Out Price If Taisho Disagrees With Their Demand - Nikkei
Brief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Tender Offer Price If Taisho Disagrees Their Demand - Nikkei
Activist fund Oasis says it may take legal action over Taisho's management buyout
Brief: Curi RMB Capital Opposes Taisho Pharmaceutical HD's Management Buyout
To Retire Treasury Shares Worth 3.65% Of Outstanding Stock On April 10